Granulomatosis with Polyangiitis clinical trials
13 active trials name this condition. Describe your situation to see which ones you may be eligible for.
Refine by biomarker
By location
- Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.
- CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis
- Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
- Pharmacokinetics Of Emulsified Avacopan Applied By NG Tube
- A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
- Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
- Clinical Transcriptomics in Systemic Vasculitis (CUTIS)
- VCRC Tissue Repository
- Vasculitis Pregnancy Registry
- Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
- One-Time DNA Study for Vasculitis
- TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Granulomatosis with Polyangiitis” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.